What is the significance of an elevated hematocrit of 55.7% with a hemoglobin of 16.9 g/dL and RBC count of 6.06 ×10^12/L, and what are the appropriate next steps in evaluation and management?

Elevated Hematocrit Requires Immediate Evaluation for Polycythemia Vera

Your patient's hematocrit of 55.7% exceeds the diagnostic threshold for polycythemia vera (PV) and requires urgent workup including JAK2 mutation testing, even though the hemoglobin appears borderline normal at 16.9 g/dL.

Why This Matters

The hematocrit of 55.7% is critically elevated and meets WHO diagnostic criteria for PV in both men (>49%) and women (>48%) 1. This level carries significant thrombotic risk—the landmark CYTO-PV study demonstrated that maintaining hematocrit <45% versus 45-50% reduced cardiovascular death and major thrombotic events from 9.8% to 2.7% (P=.007) 2. Your patient is well above even the higher-risk threshold.

The Hemoglobin-Hematocrit Discordance

The "normal" hemoglobin of 16.9 g/dL alongside markedly elevated hematocrit (55.7%) and RBC count (6.06) represents a critical diagnostic pattern:

• This discordance suggests either iron deficiency or microcytosis masking the true severity of erythrocytosis 3, 4
• The hematocrit-to-hemoglobin ratio (HHR) here is 3.30, which is elevated and in PV patients correlates with iron deficiency, stronger clonal myeloproliferation, shorter time to thrombosis (HR 5.20), and worse overall survival (HR 6.69) 3
• Iron deficiency can lower hemoglobin while hematocrit remains markedly elevated, potentially delaying PV diagnosis 1

Immediate Next Steps

1. Order JAK2 Mutation Testing Immediately

• JAK2 V617F mutation (present in ~95% of PV cases)
• If negative, test for JAK2 exon 12 mutations 1

2. Complete the Diagnostic Workup

• Iron studies (ferritin, serum iron, TIBC) - essential given the HHR pattern
• Serum erythropoietin level (typically low in PV)
• Complete metabolic panel to assess for secondary causes
• Bone marrow biopsy if JAK2 positive or high clinical suspicion - look for hypercellularity with trilineage growth (panmyelosis) 1

3. Assess for Secondary Causes

• Hypoxia-related: Sleep apnea, chronic lung disease, high altitude, smoking history, cyanotic heart disease
• Renal pathology: Renal artery stenosis, polycystic kidney disease, renal tumors
• Other tumors: Hepatocellular carcinoma, cerebellar hemangioblastoma
• Testosterone or erythropoietin use

4. Evaluate Thrombotic Risk Immediately

• History of prior thrombosis (arterial or venous)
• Cardiovascular symptoms: headaches, chest pain, erythromelalgia, visual disturbances
• Splenomegaly on exam
• Age >60 years (high-risk category) 2

Management Pending Diagnosis

Start aspirin 81-100 mg daily immediately unless contraindicated (acquired von Willebrand disease risk, active bleeding) 2. The ECLAP study showed 60% reduction in combined thrombotic events with aspirin in PV patients (P=.03).

Consider therapeutic phlebotomy now given the hematocrit of 55.7%:

• Target hematocrit <45% based on CYTO-PV trial evidence 2
• This is appropriate even before definitive diagnosis given the thrombotic risk at this hematocrit level
• Remove 250-500 mL initially, monitor closely

Common Pitfalls to Avoid

1. Don't dismiss this as "normal" based on hemoglobin alone—the hematocrit is the critical value here and clearly abnormal 1

2. Don't delay workup for iron replacement—while formal PV diagnosis may require demonstrating criteria after iron replacement for research purposes, you should not delay the working diagnosis or thrombosis prevention in clinical practice 1

3. Don't assume this is relative/spurious polycythemia at hematocrit 55.7%—this level typically indicates true erythrocytosis requiring full evaluation 5

4. Don't overlook the elevated RBC count (6.06)—this supports true erythrocytosis rather than hemoconcentration alone

If JAK2 Positive: Confirm PV Diagnosis

Per revised WHO criteria 1, PV diagnosis requires:

• Major criteria: Both hemoglobin >18.5 g/dL (men) or >16.5 g/dL (women) OR hematocrit >49% (men) or >48% (women) AND JAK2 mutation
• Plus one minor criterion: Bone marrow hypercellularity with panmyelosis OR low serum erythropoietin

Your patient already meets the hematocrit threshold; if JAK2 positive plus one minor criterion, PV is confirmed.

Risk Stratification and Long-term Management

If PV confirmed, stratify as:

• High-risk (age >60 OR prior thrombosis): Requires cytoreductive therapy (hydroxyurea or interferon) plus aspirin and phlebotomy to maintain hematocrit <45% 2
• Low-risk (age ≤60 AND no prior thrombosis): Aspirin plus phlebotomy to maintain hematocrit <45% 2

The elevated hematocrit-to-hemoglobin ratio pattern suggests this patient may have more aggressive disease biology requiring closer monitoring even within their risk category 3.